SuspendedNot Applicable

Cryotherapy & Oxaliplatin

Stopped: Study paused to enrollment

United States40 participantsStarted 2025-03-13

Plain-language summary

The primary objective of this study is to determine if cryotherapy is beneficial to patients with colon cancer who are receiving oxaliplatin in the prevention of developing chemotherapy induced peripheral neuropathy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Over the age of 18 years * Willingness to participate in research * Diagnosed with stage III colon cancer * Chemotherapy naïve * Planning to initiate Capecitabine + Oxaliplatin (CAPOX) chemotherapy regimen as part of standard of care. Exclusion Criteria: * Pre-existing peripheral neuropathy * Pre-existing diabetes * Raynaud's disease * Metabolic syndrome, including: Hypertension; Hypercholesterolemia; and Obesity (BSA \> 2) * Upper extremity amputees * Specific autoimmune diseases: Guillain-Barre; Lupus; Rheumatoid arthritis; and Sjogren's syndrome

What they're measuring

Proportion of Participants with Peripheral Neuropathy at Visit 2

Timeframe: Visit 2 (Day 1)

Proportion of Participants with Peripheral Neuropathy at Visit 3

Timeframe: Visit 3 (Day 21)

Proportion of Participants with Peripheral Neuropathy at Visit 4

Timeframe: Visit 4 (Day 42)

Proportion of Participants with Peripheral Neuropathy at Visit 5

Timeframe: Visit 5 (Day 63)

Trial details

NCT IDNCT06281925

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-04-30

View on ClinicalTrials.gov More Colon Cancer trials